AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
UHS
ACCE-researched

Universal Health Services Inc. Common Stock (UHS) fair value

Healthcare · Medical Care Facilities · NYSE · United States
$186.89-0.66%
Market cap $11.1BNext earnings 2026-10-27Updated Oct 19, 2026
Add earnings to calendarGoogle
Our verdict
Trades 40% below our fair value
Price
$186.89
Model fair valueConfidence: good
$309
Model range
$253 to $412
Fair value $309
Price $187
3 models fit Universal Health Services Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Gold84
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionUniversal Health Services Inc. Common Stock (UHS)
Fair value (3 models)
$309
ACCE price target
$205
Rating
Undervalued
Horizon
12 months
Fair value published on 19 Oct 2026, 19:04 CEST; previously $376 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 27 Sept 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 19:04 CEST.
Price used: $187 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
39.6% below
+65.6% to fair value
ACCE score
71
out of 100
Analysts
35% buy
20 covering
P/E
7.7x
forward 7.3x
1-year return
-10.4%
Dividend yield
0.44%

Universal Health Services Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Universal Health Services runs acute care hospitals and behavioral health facilities across the US and the UK, and it is one of the few large operators with meaningful scale in psychiatric inpatient care, a segment where bed capacity is hard to build quickly. That scarcity gives it pricing and referral leverage that general acute hospitals often lack. Revenue is growing 8.3% with a 44.6% gross margin and an 11.1% operating margin, and return on equity of 20.9% suggests the capital base is being used efficiently. At a trailing P/E of 7.3 and a forward P/E of 7.5, the market is pricing in little growth, which makes the company worth a closer look to test whether behavioral demand and bed additions can keep margins from compressing. The key diligence questions are payer mix, Medicaid and exchange exposure, and how much of recent growth came from volume versus rate.

AI-assisted·How I use AIWritten Oct 14, 2026
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
  • moderate
    ACCE quality score weak
    Quality component at 40/100 is notably below overall score of 66. Suggests operational or earnings quality concerns warrant scrutiny despite strong valuation metrics.
  • moderate
    Debt load in healthcare sector
    Debt/Equity of 0.69 is material for a capital-intensive healthcare operator. Refinancing risk and margin pressure from rising rates merit monitoring.

AI research notes

AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • The company generated 20.9% ROE and 10.1% ROIC while returning capital through 5.1% annual share buybacks, signaling disciplined capital allocation.
  • Revenue has grown 8.3% year over year and 9.0% on a 5-year basis, with latest earnings beating expectations by 5.7%.
Why it could disappoint
  • The stock's current price implies only 3.1% annual cash flow growth over the next five years, leaving little room for disappointment.
  • Analyst consensus assigns a 108.8% upside to fair value, but only 35% of analysts rate the stock Buy or Strong Buy.
  • At 4.8% free cash flow yield with a 0.69 debt-to-equity ratio, UHS offers modest returns relative to the 5.2% risk-free rate.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 27, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where UHS's valuation models land
Price
$186.89
Model fair value
$309
Model range
$253 to $412
Fair value $309
Price $187
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish35% buy · 20 covering analysts
● Strong buy 6● Buy 1● Hold 12● Sell 1● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+1.0%
1 month
+3.0%
3 months
+20.0%
6 months
+7.2%
YTD
-14.3%
1 year
-10.4%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
19 Oct 2026, 19:04 CESTRatingUndervaluedfirst publication$185
19 Oct 2026, 19:04 CESTFair value$309$376$185
15 Oct 2026, 00:00 CESTFair value$376$370$179
11 Oct 2026, 00:00 CESTFair value$370$391$177
27 Sept 2026, 00:00 CESTACCE price target$205first publication$179
26 Sept 2026, 00:00 CESTFair value$391$314$177
23 Sept 2026, 00:00 CESTFair value$314$399$175
19 Sept 2026, 00:00 CESTFair value$399$316$181
14 Sept 2026, 00:00 CESTFair value$316$320$175
12 Sept 2026, 00:00 CESTFair value$320$324$173

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full UHS page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth60Value95Quality73Momentum56Total71
Valuation
Trailing P/E
7.7x
Forward P/E
7.3x
PEG
1.21
P/B
1.41x
EV / Revenue
0.9x
Book value/sh
$127.49
Enterprise value
$15.7B
Profitability
ROE
20.9%
FCF yield
7.66%
ROIC
9.6%
Health and risk
Debt / equity
0.76
Dividend yield
0.44%
Beta
1.03

Price

-11.3% · 1Y

Ask anything about UHS

Answered from Universal Health Services Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 7.7x7.7xhigh 53.2x
ROEbetter than 60% of peers
low 9%21%high 88%
Div yieldbetter than 50% of peers
low 0.0%0.4%high 3.9%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
UHS Universal Health Services Inc. Common Stock$186.89$30940% below7.7x20.9%7371
APOLLOHOSP.NS Apollo Hospitals Enterprise Limited₹7604.50--53.2x-5950
DVA DaVita Inc. Common Stock$186.10$26329% below15.7x88.5%6476
ENSG The Ensign Group Inc. Common Stock$178.35$12641% above27.5x17.0%5056
FMS Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)$22.23$3333% below11.7x8.5%5655
FME.DE Fresenius Medical Care€39.18€5832% below12.2x8.5%5155
EHC Encompass Health Corporation Common Stock$126.01$9631% above20.8x25.0%7269

Sector report card

Where UHS ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 9, 2026
    Universal Health Services, Inc. Announces Date and Time Change for Third Quarter 2026 Earnings Release and Conference Call
  • GlobeNewswire•Oct 5, 2026
    Universal Health Services, Inc. Announces Date for Third Quarter 2026 Earnings Release and Conference Call
  • PR Newswire•Aug 25, 2026
    UNIVERSAL HEALTH SERVICES, INC. TO PRESENT AT SEPTEMBER HEALTHCARE CONFERENCES
4 more press releases · full archive on Investor+.INVESTOR
40 filings
August 2026
Aug 21
8-KCurrent reportPeriod 2026-08-20
View on SEC →
Aug 17
8-KCurrent reportPeriod 2026-08-17
View on SEC →
Aug 13
8-KCurrent reportPeriod 2026-08-11
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR